KR20010083662A - Antiviral and Anticancer Agents - Google Patents

Antiviral and Anticancer Agents Download PDF

Info

Publication number
KR20010083662A
KR20010083662A KR1020000007658A KR20000007658A KR20010083662A KR 20010083662 A KR20010083662 A KR 20010083662A KR 1020000007658 A KR1020000007658 A KR 1020000007658A KR 20000007658 A KR20000007658 A KR 20000007658A KR 20010083662 A KR20010083662 A KR 20010083662A
Authority
KR
South Korea
Prior art keywords
extract
unsaturated fatty
ginseng
sesame
fatty acid
Prior art date
Application number
KR1020000007658A
Other languages
Korean (ko)
Inventor
손남율
Original Assignee
손남율
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 손남율 filed Critical 손남율
Priority to KR1020000007658A priority Critical patent/KR20010083662A/en
Publication of KR20010083662A publication Critical patent/KR20010083662A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/25Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258Panax (ginseng)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30Extraction of the material
    • A61K2236/37Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

PURPOSE: Provided are antiviral and antitumor agents which have an inhibiting effect on retrovirus and destroy malignant tumor(cancer) without causing any side effects. And their preparation is also provided. CONSTITUTION: The antiviral and antitumor agents comprise unsaturated fatty acid extract of sesame and alkaline extract of ginseng. The unsaturated fatty acids are extracted from sesame by compressing without heating to produce an unsaturated fatty acids extract. An extract of ginseng is obtained by dipping the ginseng into hot water and then filtering the water through a sanitary cotton to produce an alkaline extract. The amount of water used for such extraction should be about 5 to 1000 times as much as the weight of ginseng. The unsaturated fatty acid extract of sesame and the alkaline extract of ginseng are mixed in a mixing ratio of about 1 to 1-5. The mixed extract is useful for the prevention of HIV, influenza virus, herpes virus, simplex virus, rotavirus and hepatitis virus infections, and the treatment of malignant tumor.

Description

항바이러스제 및 항암제{.}Antiviral and Anticancer Agents {.}

본 발명은 유효성분으로서 참깨의 불포화지방산과 인삼의 알칼리 합성 추출물로 이루어지는 항바이러스제 및 항암제에 관한 것이다. 종래의 수많은 항바이러스제 및 항암제가 알려져 왔다 그러나 항바이러스제는 주로 박테리아에만 효과가 있는 것으로 바이러스에만 효과가 있는 것으로 바이러스에 대한 효과는 있다고 해도 극히 미약한 것이며 더욱이 항생물질은 통상 부작용을 지니고 있어 때때로 아주 혹독하고 심각한 것으로 될 수 있다.The present invention relates to an antiviral agent and an anticancer agent composed of an alkaline synthetic extract of unsaturated fatty acid of ginseng and ginseng as an active ingredient. Numerous antiviral and anticancer drugs have been known in the past, but antiviral drugs are mainly effective only on bacteria and are effective only on viruses, even if they are effective against viruses. Moreover, antibiotics usually have side effects, which are sometimes very harsh. And can be serious.

인플루엔자, 식욕부진, 피로회복, 구토, 신경와약, 췌장암, 성인T-세포, 당뇨병 및 AIDS등의 바이러스에 의해 많은 질병이 발생하나 불행하게도 이들 종래의 바이러스성 질병에 대해서 명확한 효능을 보이는 약물치료는 거의 없는 실정이고 특히 아무 부작용없이 항당뇨 또는 에이즈를 일으키는 레트로 바이러스에 대해 충분히 효과적인 의약은 없었다. 또한 일일식이요법에서 취할 수 있었고 아무 부작용없이 예방효과를 지니는 항바이러스제에 대해서도 알려진 것이 없었다. 따라서 부작용을 지니지 않는 에이즈 및 에이즈에 관련 콤플렉스의 효율적인 치료에 관한 연구는 특히 어려워서 장기간의 화학요법을 통해 제한된 효과를 나타내는 몇몇 의약은 심각한 부작용을 보일 수 있다. 항암제로서 지금까지 알려진 항암제는 암세포를 파괴할뿐만아니라 정상세포까지도 손상시킬 수 있도록 작용하였기 때문에 이들 항암제는 혹독한 부작용을 보여 왔다. 또 이들 항암제는 구강투여를 사용하기가 곤란하였기 때문에 통상 정맥주사로 사용되여 왔던바 이들 항암제는 많은 문제가 존재하고 있었다. 그러므로 항HIV 및 항암제는 부작용이 없고 세포상의 바이러스 흡착을 지니는 제제를 발명해야 할 필요가 있었다. 따라서 본 발명의 목적은 상기 문제점을 해결하여 레트로 바이러스에 대한 효능이 있고 부작용없이 악성종양(암)을 파괴하는 항암제를 제공하는 것이다. 본 발명자는 상기 문제를 해결하기 위해 예의 연구한 결과 참깨의 불포화 지방산, 인삼의 알칼리 추출물이 강한 항바이러스 및 항암작용을 지니고 상기 불포화 지방산, 알칼리추출물이 동물 또는 안간에 대해 극히 안전하고 부작용을 지니지 않는다는 것을 발견하여 본 발명을 개발하였다.Many diseases are caused by viruses such as influenza, anorexia, fatigue, vomiting, neuropharmaceuticals, pancreatic cancer, adult T-cells, diabetes, and AIDS, but unfortunately, drug treatments that show clear efficacy against these conventional viral diseases are There are few drugs that are effective enough, especially against retroviruses that cause antidiabetic or AIDS without any side effects. There was also no known antiviral agent that could be taken in daily diets and had a preventive effect without any side effects. Therefore, studies on the effective treatment of AIDS and AIDS-related complexes that do not have side effects are particularly difficult, and some medications that have limited effects through long-term chemotherapy may have serious side effects. Since anticancer drugs known as anticancer drugs have not only destroyed cancer cells but also damaged normal cells, these anticancer drugs have had severe side effects. In addition, since these anticancer drugs were difficult to use oral administration, there have been many problems with these anticancer drugs. Therefore, there was a need to invent an agent having anti-HIV and anti-cancer agents without side effects and having viral adsorption on cells. It is therefore an object of the present invention to provide an anticancer agent that is effective against retroviruses and destroys malignant tumors (cancer) without side effects by solving the above problems. The present inventors have diligently researched to solve the above problem, and the unsaturated fatty acids of sesame and alkali extracts of ginseng have strong antiviral and anticancer effects, and the unsaturated fatty acids and alkali extracts are extremely safe for animals or eyes and have no side effects. The present invention was developed.

본 발명의 유효성분은 참깨를 정선수세하여 수분 15% 건조후 가열하지 않고 압착하여 불포화 지방산 추출물에서 유도된다. 보다 바람직하게 인삼를 정선수세하여 온수에서 추출한 다음 알칼리 용액과 불포화지방산을 약 1:1내지 5의 비율로 합성하여 유도된다. 가열하지 않고 압착 추출한 다음 불포화지방산 용액으로 추출해서 유도된 다음 추출공정에 있어서 물의 양은 인삼의 중량이 5-1000배이어야 하며 70-100℃에서 5분-10시간 동안 추출한다.The active ingredient of the present invention is derived from unsaturated fatty acid extracts by pressing the sesame seed and pressing it without heating after drying 15% of moisture. More preferably, ginseng is extracted with hot water, extracted from hot water, and then synthesized with an alkaline solution and unsaturated fatty acid in a ratio of about 1: 1 to 5. Extraction is carried out by pressing without heating and then extracted with unsaturated fatty acid solution. In the extraction process, the amount of water should be 5-1000 times the weight of ginseng and extracted for 5 minutes-10 hours at 70-100 ℃.

불포화 지방산 특정 예로는 단백질, 아미노산, 메타오닌, 기질, 칼슘과 알칼리용액의 특정예로는 panacene, falcarinol이 28종류의 saponin성분,ginsenosidRx(x=o, a, b1, b2, c, d, e, f, g1, g3, h1, h2) 등을 들수 있다. 온수 추출등의 공지와 추출법을 사용할 수도 있다. 추출용액의 분리는 여과 레칸테이션, 원심분리 등의 공지와 방법으로 행할 수 있다. 물이위에 추출용매로서 에탄올, 이세톤 등을 사용할 수 있다.Specific examples of unsaturated fatty acids include proteins, amino acids, methionine, substrates, calcium and alkaline solutions. Specific examples of panacene and falcarinol include 28 kinds of saponin components, ginsenosidRx (x = o, a, b1, b2, c, d, e. , f, g1, g3, h1, h2), and the like. Known methods and extraction methods such as hot water extraction can also be used. Separation of the extraction solution can be carried out by known methods such as filtration recantation, centrifugation and the like. Ethanol, isetone, etc. can be used as an extraction solvent on water.

상기 추출물의 유효성분을 부형제, 결합제, 휘석재 등의 적당한 담체와 혼합할 수 있고 예를 들면 캡슐제, 연고제, 시럽, 좌약제, 주사제로서 경구용 혹은 비경구용으로 또는 혼합하여 그대로 용액, 캡슐의 형태로 단독 투여, 농축액을 이용 또는 다른 음식물에 혼합하여 사용할 수 있다.The active ingredient of the extract may be mixed with a suitable carrier such as excipients, binders, or ignition materials, and for example, capsules, ointments, syrups, suppositories, injections, orally or parenterally, or mixed as it is, In the form of a single dose, the concentrate may be used or mixed with other foods.

투여량은 대상으로되는 질환의 종류, 정도에 따라 다르나, 액체형태일 경우는 1∼100mg 1용액을 1ml∼500ml로 투여해야 한다.The dosage depends on the type and severity of the disease. However, in the liquid form, 1 ml to 1 mg to 500 ml should be administered.

참깨의 불포화지방산 추출물과 인삼의 알칼리 추출물을 약 1:1내지 5의 비율로 합성하여 쥐 및 생쥐에 대해 시험을 행한바 사망률은 없고 동물의 이상행동이 관측되지 않으며 혈액의 생화학시험 및 조직의 병리학 실험에 있어 값이 나타나지 않는다.Unsaturated fatty acid extracts of sesame and alkali extracts of ginseng were synthesized in a ratio of 1: 1 to 5, and mice and mice were tested. No mortality was observed and abnormal behavior of animals was not observed. No value appears in the experiment.

본 발명은 항바이러스제, 항암제, 항박테리아제 및 살균제, 살충제로서 본 발명에 의하면 인플루엔자 바이러스 헤르페스, 신플렉스바이러스(단순포진바이러스), 로타바이러스 및 간염바이러스 등의 각종 바이러스 등의 레트로 바이러스의 감염을 방지하고 복제를 억제하며 또 박테리아, 곰팡이등의 미생물의 성장 혹은 관상을 방지하며, 또한 아무런 부작용을 일으키지 않으면서 악성종양을 향상 및 치료하는 추출물을 얻을 수 있다.The present invention is an antiviral agent, an anticancer agent, an antibacterial agent and a bactericide, and an insecticide. According to the present invention, infection of various viruses such as influenza virus herpes, sinplex virus (simple herpes virus), rotavirus, and hepatitis virus is prevented. In addition, it inhibits replication and prevents the growth or coronation of microorganisms such as bacteria and fungi, and also obtains extracts that enhance and treat malignant tumors without causing any side effects.

실시 예Example

제조 예1Manufacturing Example 1

참깨를 정선수세하여 수분 15% 건조후 가열하지 않고 압착추출하고 인삼를 정선수세하여 햇빛 건조의 공정을 행하여 건조한다.The sesame seeds are washed with water and dried 15% of moisture, then compressed without heating, and the ginseng is washed with water, followed by the drying process of sunlight.

이들 건조된 인삼 3g을 85℃의 온수 100mu에서 3시간 동안 추출한 다음 위생면(두께 0.5cm)를 통해 여과하여 각종의 산성과 당류를 함유하는 추출액을 얻는다. 참깨의 불포화지방산 추출물과 인삼의 알칼리 추출물을 약 1:1내지 5의 비율로 합성추출액을 얻는다.3 g of these dried ginseng are extracted for 3 hours in 100 mu of hot water at 85 ° C., and then filtered through a sanitary cotton (thickness of 0.5 cm) to obtain an extract containing various acids and sugars. Unsaturated fatty acid extracts of sesame and alkali extracts of ginseng are obtained at a ratio of about 1: 1 to 5.

제조 예2Manufacturing Example 2

불포화지방산과 알칼리용액으로서 제조1과 동일방법으로 1:1로 합성한 추출물을 얻는다.As an unsaturated fatty acid and an alkaline solution, an extract synthesized 1: 1 is obtained in the same manner as in Preparation 1.

제조 예3Manufacturing Example 3

알칼리 용액을 여과를 위해 위생면 대신에 거즈 1통을 사용하여 제조1과 동일방법으로 추출물을 약 1:1내지 5의 비율로 합성한 추출물을 얻는다.In the same manner as in Preparation 1, an extract obtained by synthesizing the alkaline solution in the ratio of about 1: 1 to 5 was obtained by using one gauze bucket instead of the sanitary cotton for filtration.

실험 예1Experimental Example 1

제조 예1에서 얻은 합성물을 배양된 MDCK 세포 또는 MA104세포에 도포한다. 도포직후 MDCKㅡ를 인플루엔자 바이러스로 감염시키고 MA104를 헤르테르신플렉스 바이러스로 감영시키고, 합성물에 의해 자발적으로 배양하면 플랙형성이 관찰된다.그 결과 인플루엔자 바이러스에 의한 플랙(반점)은 0.1mg/m1의해 완전히(100%) 억제되며 헤르페스바이러스 플랙형성의 경우 상기 추출물의 1ug/m1에 의해 90% 이상으로 억제됨을 보인다.The composite obtained in Preparation Example 1 is applied to cultured MDCK cells or MA104 cells. Immediately after application, MDCK- was infected with influenza virus, MA104 was sensitized with hertersinplex virus, and spontaneous incubation with the compound resulted in flaking formation. It is completely (100%) inhibited and is shown to be inhibited by more than 90% by 1ug / m1 of the extract in case of herpes virus flaming.

실험 예2Experimental Example 2

MT-4세포(2.5×104세포/웰)을 HIV-1로 감염시키고 감염된 세포를 제조예 1에서 얻은 상기 추출물을 각종 농도로 함유하는 96개의 웰을 지닌 마이크로치터플레이드에 펼쳐 바르고, CO2인큐베이터의 37℃에서 5일간 배양한다. 생존 세포의 수를 MTT법으로 측정한다. 항 HIV활성은 데스트물질에 의한 HIV로 인한 세포파괴에 대해 50% 보호를 보이는 농도로 표현한다.(EC50:50% 유효농도) EC 50은 21ug/m1이하이다.MT-4 cells (2.5 × 10 4 cells / well) were infected with HIV-1 and the infected cells were spread over a microchiterplate containing 96 wells containing various concentrations of the extract obtained in Preparation Example 1, followed by CO Incubate at 37 ° C. in 2 incubators for 5 days. The number of viable cells is measured by MTT method. Anti-HIV activity is expressed in concentrations that show 50% protection against HIV-induced cell destruction (EC50: 50% effective concentration). EC 50 is less than 21 ug / m1.

실험 예3Experimental Example 3

MT-4세포(2.5×104세포/웰)를 HIV로 감염시키고 감염직후 감염된 세포를 제조 예2에서 얻은 상기 추출액을 각종 농도로 함유하는 96개의 웰을 지닌 마이크로 티터플레이트로 펼쳐 바르고, CO2인큐베이터의 37℃에서 5일간 배양한다. 생존세포의 수를 MTT법으로 측정한다. 항 HIV활성은 테스트 물질에 의한 HIV로 인한 세포파괴에 대해 50%의 보호를 나타내는 농도로서 표현한다. (EC 50 : 50% 유효농도)EC 50을 21ug/m1이하이다.Infect MT-4 cells (2.5 × 10 4 cells / well) with HIV and spread the infected cells immediately after infection with a microtiter plate with 96 wells containing various concentrations of the extract obtained in Preparation Example 2, and CO 2 Incubate at 37 ° C. for 5 days in the incubator. The number of viable cells is measured by MTT method. Anti-HIV activity is expressed as a concentration that represents 50% protection against HIV-induced cell destruction by test substances. (EC 50: 50% effective concentration) The EC 50 is less than 21 ug / m1.

실험 예4Experimental Example 4

위암에서 추출한 WVOC(1×106세포/m1)를 20마리 쥐에게 피하주사한다. 다음날부터 실험군으로서 이들 쥐들 중 10마리를 제조1에서 얻은 추출물을 100mg/m1로 매일 주사한다.WVOC (1 × 10 6 cells / m1) extracted from gastric cancer was injected subcutaneously into 20 rats. From the next day, as an experimental group, 10 of these mice were injected daily with 100 mg / m1 of the extract obtained in Preparation 1.

상기 추출물을 투여하지 않은 쥐는 대조군으로서 사용한다. 상기 추출물의 투여후 세포의 성장을 3주간 계산한다. 대조군에서 세포의 수는 현저하게 증가하는 반면 실험군에서 종양세포의 증가는 현저하게 억제된다.Mice not administered the extract were used as controls. Cell growth is calculated for three weeks after administration of the extract. The number of cells in the control group is significantly increased while the increase of tumor cells in the experimental group is significantly suppressed.

실험 예5Experimental Example 5

위암에서 적출한 NVGC-4(1×106세포/m1)를 20마리 쥐에게 피하주사한다. 다음날부터 실험군으로서 이들 쥐들중 10마리를 제조예3에서 얻은 상기추출물 500ug/mu로 매일 주사한다. 상기 추출물을 투여하지 않은 쥐는 재조군으로서 사용한다. 상기 추출물의 투여후 세포의 성장을 1달간 계산한다. 1달 후 대조군에서의 세포는 현저히 증가하여 회사영역이 다소 존재하고 몇몇 동물은 죽어 있으나 실험군에서는 세포의 수는 현저히 억제되어 있어 죽은 동물은 없었다.NVGC-4 (1 × 10 6 cells / m 1) isolated from gastric cancer was injected subcutaneously into 20 rats. From the next day, as an experimental group, 10 of these rats are injected daily with the extract of 500 ug / mu obtained in Preparation Example 3. Mice not administered the extract are used as a control group. The growth of the cells after administration of the extract is calculated for 1 month. After one month, the cells in the control group increased markedly and there was some company area, and some animals died, but the number of cells in the experimental group was significantly suppressed, so there was no dead animal.

실험 예6Experimental Example 6

위암에서 적출한 NVGC-4(1×106세포/mu)를 제조예3에서 얻은 75-서브프렉션의 각종 농도를 함유하는 96개의 웰을 지닌 사이크로티터플레이트내에 장입하고 CO2인큐베이터 37℃에서 5일간 배양한다. 생존 세포의 수를 MTT법으로 측정한다. 불포화지방산과 산성 다당류의 항암활성을 암세포의 성장을 50% 억제하는농도(IC50:50%유효농도)로서 표현한다. 75-서브프렉션의 IC50DMS 200ug/m1 이나 정제된 불포화지방산과 산성 다당류(25-75% 침전플렉션)은 종양세포의 성장을 억제하지 않는다.NVGC-4 (1 × 10 6 cells / mu) extracted from gastric cancer was loaded into a 96 well cyclator plate containing various concentrations of 75-subfraction obtained in Preparation Example 3, followed by CO 2 incubator at 37 ° C. Incubate for 5 days at. The number of viable cells is measured by MTT method. The anticancer activity of unsaturated fatty acids and acidic polysaccharides is expressed as a concentration (IC 50: 50% effective concentration) that inhibits the growth of cancer cells by 50%. The 75-subfraction IC50DMS 200ug / m1, but the purified unsaturated fatty acids and acidic polysaccharides (25-75% sedimentation) do not inhibit tumor cell growth.

Claims (6)

유효성분으로서 참깨의 불포화지방산과 인삼의 알칼리합성추출로 이루어지는 항바이러스제Antiviral agent consisting of alkaline synthetic extract of unsaturated fatty acid of sesame and ginseng as active ingredient 제1항에 있어서The method of claim 1 바이러스가 인간의 면역결핍성 바이러스(HIV)인 것을 특징으로하는 항바이러스제Antiviral agent characterized in that the virus is a human immunodeficiency virus (HIV) 제1항에 있어서The method of claim 1 불포화지방산 용액이 단백질, 아미노산, 메타오닌, 기질, 칼슘 성분과 알칼리용액이 panacene, falcarinol이 28종류의 saponin성분, ginsenosidRx(x=o, a, b1, b2, c, d, e, f, g1, g3, h1, h2 중의 하나인 것을 특징으로하는 항바이러스제Unsaturated fatty acid solution contains protein, amino acid, methionine, substrate, calcium component and alkaline solution, panacene, falcarinol contains 28 kinds of saponin components, ginsenosidRx (x = o, a, b1, b2, c, d, e, f, g1 , g3, h1, h2, characterized in that the antiviral 유효성분으로서As an active ingredient 참깨의 불포화지방산과 인삼의 알칼리 합성 추출물로 이루어지는 항암제Anticancer agent consisting of unsaturated fatty acid of sesame and alkali extract of ginseng 참깨를 가열하지 않고 압착추출하여 불포화지방산과 인삼의 온수추출에 알 칼리용액을 여과 분리하여 항바이러스제를 제조하는 방법Method of producing antiviral agent by squeezing sesame without heating sesame and filtering alkaline solution to hot water extraction of unsaturated fatty acid and ginseng 제4항에 있어서The method of claim 4 불포화지방산 용액이 단백질, 아미노산, 메타오닌, 기질, 칼슘, 알칼리 용액이 panacene, falcarinol이 28종류의 saponin성분, ginsenosidRx(x=o, a, b1, b2, c, d, e, f, g1, g3, h1, h2 중의 하나인 것을 특징으로 하는 항암제의 제조방법Unsaturated fatty acid solution contains protein, amino acid, methionine, substrate, calcium, alkaline solution, panacene, falcarinol, 28 kinds of saponin components, ginsenosidRx (x = o, a, b1, b2, c, d, e, f, g1, g3, h1, h2 is a method for producing an anticancer agent characterized in that
KR1020000007658A 2000-02-17 2000-02-17 Antiviral and Anticancer Agents KR20010083662A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020000007658A KR20010083662A (en) 2000-02-17 2000-02-17 Antiviral and Anticancer Agents

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020000007658A KR20010083662A (en) 2000-02-17 2000-02-17 Antiviral and Anticancer Agents

Publications (1)

Publication Number Publication Date
KR20010083662A true KR20010083662A (en) 2001-09-01

Family

ID=19647505

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020000007658A KR20010083662A (en) 2000-02-17 2000-02-17 Antiviral and Anticancer Agents

Country Status (1)

Country Link
KR (1) KR20010083662A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104644759A (en) * 2013-11-22 2015-05-27 富力 Health tea for preventing and/or treating influenza and preparation method thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104644759A (en) * 2013-11-22 2015-05-27 富力 Health tea for preventing and/or treating influenza and preparation method thereof

Similar Documents

Publication Publication Date Title
EP3277271B1 (en) Antiviral activity from medicinal mushrooms and their active constituents
US20050266105A1 (en) Compositions comprising natural agents for the treatment of HIV-associated opportunistic infections and complications and methods for preparing and using compositions comprising natural agents
Maiti et al. Therapeutic potentials of andrographolide from Andrographis paniculata: a review
EP3391893B1 (en) Pharmaceutical composition for treating leukemia and preparation method thereof
Ramazanov Phytoecdysteroids and Other Biologically Active Compounds from Plants of the Genus Ajuga.
EP0796620B1 (en) An anti-viral and anti-cancer agent from "Aspalathus Linearis"
KR20010083662A (en) Antiviral and Anticancer Agents
KR20010083663A (en) Antiviral and Anticancer Agents
KR20010074416A (en) Antiviral and Anticancer Agents
KR20010083661A (en) Antiviral and Anticancer Agents
EP0327461A1 (en) Use of milk proteins in making antiviral drugs
KR20120027887A (en) Antiviral and Anticancer Agents
KR20010077474A (en) Antiviral and Anticancer Agents
KR20010083664A (en) Antiviral and Anticancer Agents
KR20010083660A (en) Antiviral and Anticancer Agents
KR20010077472A (en) Antiviral and Anticancer Agents
KR20010077473A (en) Antiviral and Anticancer Agents
KR20010089923A (en) Antiviral and Anticancer Agents
KR20010077471A (en) Antiviral and Anticancer Agents
KR20010089922A (en) Antiviral and Anticancer Agents
KR20010089924A (en) Antiviral and Anticancer Agents
KR20010089921A (en) Antiviral and Anticancer Agents
KR20010089925A (en) Antiviral and Anticancer Agents
EP0753305B1 (en) Use of crude plant extract for the preparation of a medicament for treating HIV infection
TW202139995A (en) Use of ovatodiolide against sars-cov-2

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid